Incidence and management of the main serious adverse events reported after COVID‐19 vaccination
Pharmacology Research & Perspectives,
Journal Year:
2024,
Volume and Issue:
12(3)
Published: June 1, 2024
Coronavirus
disease
2019
(COVID-19)
caused
by
the
severe
acute
respiratory
syndrome
coronavirus
2n
first
appeared
in
Wuhan,
China
2019.
Soon
after,
it
was
declared
a
pandemic
World
Health
Organization.
The
health
crisis
imposed
new
virus
and
its
rapid
spread
worldwide
prompted
fast
development
of
vaccines.
For
time
human
history,
two
vaccines
based
on
recombinant
genetic
material
technology
were
approved
for
use.
These
mRNA
applied
massive
immunization
programs
around
world,
followed
other
more
traditional
approaches.
Even
though
all
tested
clinical
trials
prior
to
their
general
administration,
serious
adverse
events,
usually
very
low
incidence,
mostly
identified
after
application
millions
doses.
Establishing
direct
correlation
(the
cause-effect
paradigm)
between
vaccination
appearance
effects
has
proven
challenging.
This
review
focuses
main
observed
vaccination,
including
anaphylaxis,
myocarditis,
vaccine-induced
thrombotic
thrombocytopenia,
Guillain-Barré
syndrome,
transverse
myelitis
reported
context
COVID-19
vaccination.
We
highlight
symptoms,
laboratory
tests
required
an
adequate
diagnosis,
briefly
outline
recommended
treatments
these
effects.
aim
this
work
is
increase
awareness
among
healthcare
personnel
about
events
that
may
arise
post-vaccination.
Regardless
ongoing
discussion
safety
must
be
promptly
treated
effectively
reduce
risk
complications.
Language: Английский
Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
Applied Microbiology and Biotechnology,
Journal Year:
2024,
Volume and Issue:
108(1)
Published: Jan. 27, 2024
Abstract
Several
COVID-19
vaccines
use
adenovirus
vectors
to
deliver
the
SARS-CoV-2
spike
(S)
protein.
Immunization
with
these
promotes
immunity
against
S
protein,
but
also
itself.
This
could
interfere
entry
of
vaccine
into
cell,
reducing
its
efficacy.
Herein,
we
evaluate
efficiency
an
adenovirus-vectored
(chimpanzee
ChAdOx1
adenovirus,
AZD1222)
in
boosting
specific
compared
that
induced
by
a
recombinant
receptor-binding
domain
(RBD)-based
without
viral
vector.
Mice
immunized
AZD1222
human
were
given
booster
6
months
later,
either
homologous
or
based
on
RBD
delta
variant,
which
was
prevalent
at
start
this
study.
A
significant
increase
anti-RBD
antibody
levels
observed
rRBD-boosted
mice
(31–61%)
those
receiving
two
doses
(0%).
Significantly
higher
rates
PepMix™-
RBD-elicited
proliferation
IFNγ-producing
CD4
and
CD8
cells
from
boosted
one
RBD,
respectively.
The
lower
ChAdOx1-S
be
result
pre-existing
anti-vector
immunity,
increased
anti-adenovirus
antibodies
found
both
humans.
Taken
together,
results
point
importance
avoiding
recurrent
same
vector
individuals
memory
them.
It
illustrates
disadvantages
respect
protein
vaccines,
can
used
restriction
vaccine-booster
programs.
Key
points
•
(AZD1222)
may
not
effective
anti-SARS-CoV-2
is
Antibodies
elicited
rRBD-delta
persisted
for
up
3
Language: Английский
Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity
Journal of Medical Virology,
Journal Year:
2024,
Volume and Issue:
96(2)
Published: Feb. 1, 2024
Abstract
With
the
approval
of
first
vaccines
against
respiratory
syncytial
virus
(RSV)
and
a
novel
RSV‐neutralizing
antibody,
2023
has
been
perceived
as
game‐changing
year
in
preventing
severe
outcomes
RSV
infections
infants
elderly.
However,
costs
these
pharmaceuticals
are
high,
while
disproportionately
impacts
populations
low‐to‐middle‐income
regions,
which
may
continue
to
suffer
from
lack
pharmaceutical
measures
for
prevention
under
health
socioeconomic
disparities.
This
paper
presents
an
overview
characteristics,
clinical
results,
status
various
anti‐RSV
antibodies.
It
posits
that
wealthy
nations
cannot
monopolize
immunoprophylaxis
should
work
jointly
make
it
available
lower‐income
countries.
An
approach
toward
equity
based
on
five
points
is
offered:
(1)
integration
antibodies
into
existing
global
humanitarian
distribution
systems,
(2)
using
affordable
vaccine
pricing
models,
(3)
enforcing
part
national
public
strategy,
(4)
implementing
equitable
allocation
frameworks
immunoprophylaxis,
(5)
promoting
local
manufacturing.
Such
plan
needs
be
put
action
soon
possible
avoid
delays
serving
with
highest
related
burden.
Language: Английский
Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches
Journal of Medical Virology,
Journal Year:
2024,
Volume and Issue:
96(9)
Published: Sept. 1, 2024
Abstract
Despite
remarkable
progress
in
the
treatment
of
hepatitis
C
virus
(HCV)
infection,
it
remains
a
significant
global
health
burden,
necessitating
development
an
effective
prophylactic
vaccine.
This
review
paper
presents
current
landscape
HCV
vaccine
candidates
and
approaches,
including
more
traditional,
based
on
inactivated
virus,
modern,
such
as
subunit
protein,
vectored,
nucleic
acids
(DNA
mRNA)
virus‐like
particles.
The
concept
is
first
put
context
viral
genetic
diversity
adaptive
responses
to
understanding
which
crucial
guiding
against
complex
virus.
Because
ethical
dimensions
are
also
research,
development,
potential
deployment,
we
address
them
this
paper.
road
safe
prevent
infection
bumpy
due
variation
its
ability
evade
immune
responses.
cell‐culture
systems
allowed
for
production
candidate,
can
induce
cross‐neutralizing
antibodies
vitro
,
but
whether
could
humans
unknown.
Subunit
protein
that
entered
clinical
trials
elicited
HCV‐specific
humoral
cellular
responses,
though
be
shown
they
translate
into
prevention
or
progression
chronic
state.
Such
were
induced
by
clinically
tested
vector‐based
decreased
load
did
not
infection.
These
disappointments
readily
predicted
from
preclinical
animal
studies.
platforms
employing
particles,
DNA,
mRNA
provide
opportunities
vaccine,
their
has
yet
shown.
Ensuring
designed
conserved
epitope(s)
elicits
broadly
neutralizing
essential.
Given
failures
developing
continue
supporting
national
strategies,
funding
screening
programs.
However,
these
actions
likely
insufficient
permanently
control
encouraging
further
mobilization
resources
research
missing
element
elimination
public
health.
Language: Английский
The Ambivalence of Post COVID-19 Vaccination Responses in Humans
Biomolecules,
Journal Year:
2024,
Volume and Issue:
14(10), P. 1320 - 1320
Published: Oct. 17, 2024
The
Coronavirus
disease
2019
(COVID-19)
pandemic,
caused
by
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2),
has
prompted
a
massive
global
vaccination
campaign,
leading
to
the
rapid
development
and
deployment
of
several
vaccines.
Various
COVID-19
vaccines
are
under
different
phases
clinical
trials
include
whole
virus
or
its
parts
like
DNA,
mRNA,
protein
subunits
administered
directly
through
vectors.
Beginning
in
2020,
few
mRNA
(Pfizer-BioNTech
BNT162b2
Moderna
mRNA-1273)
adenovirus-based
(AstraZeneca
ChAdOx1-S
Janssen
Ad26.COV2.S)
were
recommended
WHO
for
emergency
use
before
completion
phase
3
4
trials.
These
mostly
two
three
doses
at
defined
frequency
between
doses.
While
these
vaccines,
mainly
based
on
viral
nucleic
acids
conferred
protection
against
progression
SARS-CoV-2
infection
into
COVID-19,
prevented
death
due
disease,
their
also
been
accompanied
plethora
side
effects.
Common
effects
localized
reactions
such
as
pain
injection
site,
well
systemic
fever,
fatigue,
headache.
symptoms
generally
mild
moderate
resolve
within
days.
However,
rare
but
more
serious
have
reported,
including
allergic
anaphylaxis
and,
some
cases,
myocarditis
pericarditis,
particularly
younger
males.
Ongoing
surveillance
research
efforts
continue
refine
understanding
adverse
effects,
providing
critical
insights
risk-benefit
profile
Nonetheless,
overall
safety
supports
continued
combating
with
regulatory
agencies
health
organizations
emphasizing
importance
preventing
COVID-19's
outcomes.
In
this
review,
we
describe
types
summarize
various
autoimmune
inflammatory
response(s)
manifesting
predominantly
cardiac,
hematological,
neurological,
psychological
dysfunctions.
incidence,
presentation,
risk
factors,
diagnosis,
management
possible
mechanisms
contributing
discussed.
review
highlights
potential
ambivalence
human
response
post-COVID-19
necessitates
need
mitigate
Language: Английский
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2
Muralimanohara S. T. Murala,
No information about this author
Vivek Gairola,
No information about this author
Ekramy E. Sayedahmed
No information about this author
et al.
Vaccines,
Journal Year:
2025,
Volume and Issue:
13(4), P. 406 - 406
Published: April 14, 2025
This
review
systematically
revises
adenovirus
(Ad)
biology,
vector
structure,
immune
responses,
and
currently
available
Ad
COVID-19
vaccines.
It
analyzes
the
challenges
associated
with
vector-based
vaccines,
including
preexisting
immunity
other
side
effects.
Moreover,
this
explores
novel
innovative
strategies
to
overcome
these
constraints
for
developing
next-generation
vaccines
broad
protection
cover
emerging
SARS-CoV-2
variants.
The
future
refinement
of
vaccine
platforms
will
be
pivotal
in
achieving
durable
against
variants
global
preparedness.
Language: Английский
BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine
iScience,
Journal Year:
2023,
Volume and Issue:
26(9), P. 107612 - 107612
Published: Aug. 11, 2023
Recent
publications
have
explored
intranasal
(i.n.)
adenovirus-based
(Ad)
vaccines
as
an
effective
strategy
for
SARS-CoV-2
in
pre-clinical
models.
However,
the
effects
of
prior
immunizations
and
infections
yet
to
be
considered.
Here,
we
investigate
immunomodulatory
Mycobacterium
bovis
BCG
pre-immunization
followed
by
vaccination
with
S-protein-expressing
i.n.
Ad,
termed
Ad(Spike).
While
Ad(Spike)
retains
some
protective
effect
after
6
months,
a
single
administration
BCG-Danish
potentiates
its
ability
control
viral
replication
B.1.351
variant
within
respiratory
tract.
Though
did
not
affect
Ad(Spike)-generated
humoral
immunity,
it
promoted
generation
cytotoxic/Th1
responses
over
suppressive
FoxP3+
TREG
cells
lungs
infected
mice.
Thus,
this
may
prove
useful
limiting
future
pandemics
potentiating
long-term
efficacy
mucosal
context
widely
distributed
vaccine.
Language: Английский
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review
Expert Opinion on Drug Metabolism & Toxicology,
Journal Year:
2023,
Volume and Issue:
19(12), P. 951 - 967
Published: Nov. 5, 2023
Introduction
Migraine
pharmacological
therapies
targeting
calcitonin
gene-related
peptide
(CGRP),
including
monoclonal
antibodies
and
gepants,
have
shown
clinical
effect
optimal
tolerability.
Interactions
between
treatments
of
COVID-19
CGRP-related
drugs
not
been
reviewed.
Language: Английский
A Narrative Review of Neurological Complications of SARS-CoV-2 Vaccination
Journal of Neuroanaesthesiology and Critical Care,
Journal Year:
2024,
Volume and Issue:
11(01), P. 010 - 017
Published: March 1, 2024
Abstract
Adverse
reactions
to
the
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
vaccine
depict
a
tropism
for
neural
structures.
This
narrative
review
was
aimed
discuss
published
data
on
spectrum
of
neurological
side
effects
SARS-CoV-2
vaccines,
which
were
accorded
emergency
use
authorization.
The
majority
manifestations
vaccination
are
usually
mild,
brief,
self-limiting,
and
easily
manageable.
Rarely,
these
can
be
serious
nature
require
hospitalization.
High
vigilance
helps
in
early
identification
treatment
complications
leading
good
outcomes.
reported
incidence
vaccinated
population
is
miniscule,
overall
benefits
outweigh
risks
effects.
However,
it
crucial
conduct
larger
collaborative
multicenter
studies
prove
or
reject
causal
association
between
vaccines
postvaccination
Herein,
we
have
tried
summarize
various
related
literature
from
2021
mid-2023.
Language: Английский
COVID-19 aşısına bağlı yan etkiler; faydalar risklerden ağır basıyor mu?
JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH,
Journal Year:
2023,
Volume and Issue:
7(4), P. 226 - 230
Published: Nov. 21, 2023
COVID-19
vaccine-associated
adverse
effects;
benefits
outweigh
the
risks?
effects
vaccines
are
produced
with
latest
technology
in
a
very
short
time
to
get
rid
of
this
disease.
These
have
been
and
used
millions
around
world.
Although
some
simple
local
side
reported
during
immediately
after
administration
vaccine,
long-term
affecting
various
organs
recently
begun
be
reported,
especially
use
mRNA
vaccines.
This
minireview
discusses
issues
related
these
less
common
effects.
Language: Английский